Tag Archives: BIOCOM

Putting the M Back in M&A

By Jennifer Ringler | Published: December 13, 2011
Joe Panetta, president and CEO of BIOCOM, discusses an emerging model of M&As in which human and IP assets are valued and biotech brings expertise to Big Pharma as venture capitalist funding dwindles and patent cliffs loom large. Pharm Exec: Can you tell me about how small biotech and specialty companies have started switching from relying [...]
Posted in Agency Insight, Biotech, Deals, FDA | Also tagged , , | Leave a comment

California Life Sciences to Partner with China

By Ben Comer | Published: April 13, 2011
BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual property (IP) protections and the Chinese government’s willingness to pay for expensive new products represent two large and lingering question marks, Joe Panetta, president and CEO at BIOCOM, [...]
Posted in Biotech, Emerging Markets, Global, IP, Market Access, R&D, leadership | Also tagged , , , | Leave a comment